Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNP-HIV-BMEP
- Development stage
- Preclinical
- Lead developer
- Centro Nacional de Biotecnología
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
LNP-HIV-BMEP is a lipid nanoparticle (LNP)-formulated mRNA vaccine candidate designed to initiate and guide broadly neutralizing antibody (bNAb) responses against HIV-1. Developed by the National Centre for Biotechnology (CNB) and the Spanish National Research Council (CSIC), the vaccine encodes the HIV-BMEP (B-cell Multiepitopic Protein) multi-epitope immunogen. This immunogen incorporates the recognition footprints of bNAbs targeting four highly conserved sites on the HIV-1 Envelope (Env) glycoprotein: the V1V2 glycan apex, the CD4 binding site, the fusion peptide, and the membrane-proximal external region (MPER). LNP-HIV-BMEP is designed to activate germline bNAb B-cell precursors. In preclinical studies, it is evaluated as a priming immunogen in a heterologous prime-boost regimen followed by a modified virus-like particle (VLP)-forming Modified Vaccinia virus Ankara (MVA) boost (MVA-ConCv5-KIKO-GPN) to elicit coordinated humoral and cellular immunity.
- Other names
- LNP-HIV-BMEP mRNA vaccinemRNA-HIV-BMEP
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on LNP-HIV-BMEP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNP-HIV-BMEP.